Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Fate Therapeutics Inc | FATE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.30 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.30 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.63 - 8.83 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 4.30 | USD |
Fate Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 427.71M | 99.24M | - | 63.53M | -160.93M | -1.62 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Fate Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FATE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.27 | 5.345 | 4.17 | 4.67 | 2,552,504 | -0.97 | -18.41% |
| 1 Month | 7.27 | 7.65 | 4.17 | 5.85 | 2,182,084 | -2.97 | -40.85% |
| 3 Months | 6.24 | 8.83 | 4.17 | 6.72 | 2,629,813 | -1.94 | -31.09% |
| 6 Months | 1.94 | 8.83 | 1.63 | 5.18 | 2,405,194 | 2.36 | 121.65% |
| 1 Year | 6.25 | 8.83 | 1.63 | 4.56 | 2,338,555 | -1.95 | -31.20% |
| 3 Years | 87.89 | 97.43 | 1.63 | 19.25 | 1,894,311 | -83.59 | -95.11% |
| 5 Years | 16.85 | 121.16 | 1.63 | 25.10 | 1,509,008 | -12.55 | -74.48% |
Fate Therapeutics Description
| Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. |
